31st Oct 2013 14:21
LONDON (Alliance News) - Omega Diagnostics Group PLC said Thursday it hopes to complete its CD4 technology transfer by the end of December.
The medical diagnostics company said it has been undertaking a number of experiments to investigate variability within the production process. The variants remaining are required to undergo further testing to select a single preferred manufacturing protocol, Omega said. This protocol will be subject to a three-batch evaluation.
CD4+ T-cells are destroyed by the HIV virus, so monitoring their count is important for the management of HIV patients being treated by antiretroviral drug therapies.
Omega produces VISITECT CD4, a disposable, semi-quantitative rapid test for the determination of CD4 counts in whole blood.
Omega shares were trading down 4.8% at 14.05 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
ODX.L